Evolus’ (EOLS) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a report issued on Wednesday,Benzinga reports. The brokerage currently has a $22.00 target price on the stock.

EOLS has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Wednesday, March 5th. Barclays increased their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th.

Evolus Trading Down 10.4 %

Shares of NASDAQ EOLS traded down $1.08 during trading on Wednesday, hitting $9.29. 645,661 shares of the company traded hands, compared to its average volume of 641,128. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $590.72 million, a P/E ratio of -10.20 and a beta of 0.97. The company has a 50-day moving average price of $13.06 and a 200-day moving average price of $13.42. Evolus has a 1 year low of $8.67 and a 1 year high of $17.82.

Insider Buying and Selling at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the sale, the chief marketing officer now directly owns 95,671 shares in the company, valued at $1,268,597.46. This trade represents a 4.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karah Herdman Parschauer sold 12,888 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the transaction, the director now directly owns 32,183 shares of the company’s stock, valued at $418,057.17. This represents a 28.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,575 shares of company stock valued at $794,369 over the last 90 days. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. KBC Group NV acquired a new stake in shares of Evolus in the 4th quarter valued at about $49,000. IFP Advisors Inc lifted its holdings in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after buying an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Evolus in the 4th quarter worth approximately $106,000. Rafferty Asset Management LLC bought a new stake in shares of Evolus in the 4th quarter valued at approximately $115,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Evolus during the 4th quarter valued at approximately $118,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.